



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 311/58, 335/06 A61K 31/35, 31/38</p>	A1	<p>(11) International Publication Number: WO 91/09853 (43) International Publication Date: 11 July 1991 (11.07.91)</p>
<p>(21) International Application Number: PCT/SE90/00863 (22) International Filing Date: 19 December 1990 (19.12.90) (30) Priority data: 8904361-6 22 December 1989 (22.12.89) SE (71) Applicant (for all designated States except US): AKTIEBOLAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): LARSSON, Lars-Gunnar [SE/SE]; Österbyvägen 35, S-150 16 Hölö (SE). NORÉEN, Rolf [SE/SE]; Kämpevägen 47, S-151 54 Södertälje (SE). RÉNYI, Lucy, Anna [SE/SE]; Hällsät-rabacken 25, S-127 37 Skärholmen (SE). ROSS, Svante, Bertil [SE/SE]; Hedvägen 8, S-151 52 Södertälje (SE). SOHN, Daniel, Dungan [US/SE]; Klinkervägen 11, S-151 55 Södertälje (SE). SVENSSON, Björn, Eric [SE/SE]; Fotbollsvägen 2, S-151 59 Södertälje (SE). THOR-BERG, Seth, Olov [SE/SE]; Gullvivsstigen 42, S-153 00 Järna (SE).</p>		<p>(74) Agents: MIKSCHE, Gerhard et al.; AB Astra, Patent Department, S-151 85 Södertälje (SE). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published With international search report.</p>
<p>(54) Title: NEW CHROMAN AND THIOCHROMAN DERIVATIVES</p>		
<p style="text-align: right;">(I)</p>		
<p>(57) Abstract Compounds of formula (I), processes for their preparation, pharmaceutical preparations, use of and method of treatment of disorders in CNS by using compounds of formula (I).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

New chroman and thiochroman derivativesDescriptionField of the Invention

5

The present invention relates to new substituted-3-amino-chromans and thiochromans, enantiomers and salts thereof, processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds as well as
10 new intermediates useful in the preparation of the therapeutically active compounds and to the use of said active compounds in therapy.

An object of the invention is to provide compounds for
15 therapeutic use, especially compounds having a therapeutic activity via the central nervous system (CNS). A further object is to provide compounds having a selective effect on the 5-hydroxy-tryptamine receptors in mammals including man.

20


Prior art

Therapeutically useful 3-amino-dihydro-[1]-benzopyran and
25 benzothiopyran having effect on 5-hydroxy tryptamine neurons in mammals are disclosed in EP 0222 996.

25

These compounds are defined by the formula

30



wherein Z is O or S;

R is hydrogen or loweralkyl;

R₁ is hydrogen, loweralkyl or arylloweralkyl;

5

R₂ is hydrogen, loweralkyl or arylloweralkyl;

or R₁ and R₂ together form a ring with 4 - 6 carbon atoms;

10

R₃ is hydrogen, hydroxy, loweralkoxy, arylloweralkoxy, acyloxy or aryloxy when Z is S and R₃ is hydroxy, loweralkoxy, arylloweralkoxy, acyloxy or aryloxy when Z is O and R₃ is in 5- or 8-position when Z is O;

15

R₄ and R₅ are independently hydrogen, lower alkyl or halogen, and mono- or di-S-oxide thereof when Z is S, and pharmaceutically acceptable salts thereof.

3-Chromanamine hydrochlorides with two alkyl groups in the aromatic ring having central stimulating activities are described in J. Med. Chem. 15, p. 863-65 (1972).

20

Disclosure of the Invention

25

The object of the present invention is to obtain new compounds which have a high affinity to the 5-hydroxy-tryptamine receptors in the central nervous system at the same time as they act as agonists, partial agonists or antagonists on the serotonin receptors.


30

35

Thus, a group of new compounds of the formula I of the present invention as well as the enantiomers and salts thereof are useful in therapeutic treatment of 5-hydroxy-tryptamine mediated states and disorders such as depression, anxiety, anorexia, senile dementia, Alzheimer's disease, migraine, termoregulator and sexual disturbances. Further aspects of the invention are related to the use of the compounds, enantiomers and salts thereof in pain control and in modulation of the cardiovascular system.

Thus, the invention provides compounds of the formula

5



I

10

I

wherein

15



20

p is an integer 0, 1 or 2;

R is hydrogen, fluoro or C₁-C₆ alkyl;

R₁ is hydrogen, C₁-C₆ alkyl or C₂-C₆ alkenyl;

25

R₂ is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkylaryl where aryl may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy;

30

R₁ and R₂ may together form a 5- or 6- membered ring which may contain 1 or 2 heteroatoms selected from N, O or S;

35

R₃ is halogen, CN, CF₃, SO₃CF₃, N₃, NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, NH₂, NR₅R₆, COR₇, 5- or 6-membered

5 aryl which may contain 1 or 2 heteroatoms selected
from N, O or S and being either (i) optionally
substituted by one or more substituents indepen-
dently selected from halogen, CN, CF₃, C₁-C₆ alkyl,
C₂-C₆ alkenyl or C₁-C₄ alkoxy or either (ii) fused
at two adjacent carbon atoms to an aryl ring, said
aryl ring being optionally substituted by one or
more substituents independently selected from
halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or
10 C₁-C₄ alkoxy;

R₄ is hydrogen or halogen;

15 R₅ is hydrogen, C₁-C₆ alkyl or C₂-C₆ alkenyl;

R₆ is C₁-C₆ alkyl or C₂-C₆ alkenyl; or


20 R₅ and R₆ may together form a 5- or 6- membered ring
which may contain 1 or 2 heteroatoms selected
from N, O or S;

25 R₇ is hydrogen, hydroxy, chloro, bromo, C₁-C₆
alkyl, C₂-C₆ alkenyl, C₁-C₄ alkoxy; NR₈ R₉ or 5-
or 6- membered aryl which may contain 1 or 2
heteroatoms selected from N, O or S optionally
substituted by one or more of halogen, CN, CF₃,
C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy;

30 R₈ and R₉ are each independently hydrogen, C₁-C₆
alkyl, C₂-C₆ alkenyl, 5- or 6- membered aryl which
may contain 1 or 2 heteroatoms selected from N, O
or S optionally substituted by halogen, CN, CF₃,
C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkoxy, or may
together form a 5- or 6- membered ring containing
35 1 or 2 heteroatoms selected from N, O or S;

enantiomers or salts thereof.

A further aspect of the invention is a pharmaceutical preparation containing as active ingredient a compound according to formula I



wherein

15

X is O or $\overset{\text{O}}{\parallel}\text{P}$ S;

p is an integer 0, 1 or 2;

20

R is hydrogen, fluoro or C₁-C₆ alkyl;

R₁ is hydrogen, C₁-C₆ alkyl or C₂-C₆ alkenyl;

25

R₂ is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkylaryl where aryl may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy; or

30

R₁ and R₂ may together form a 5- or 6- membered ring which may contain 1 or 2 heteroatoms

R₃ is halogen, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, NR₅R₆, COR₇, 5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and being either (i) optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or

35

5 C_1-C_4 alkoxy or either (ii) fused at two adjacent carbon atoms to an aryl ring, said aryl ring being optionally substituted by one or more substituents independently selected from halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl or C_1-C_4 alkoxy;

R_4 is hydrogen or halogen;

10 R_5 is hydrogen, C_1-C_6 alkyl or C_2-C_6 alkenyl;

R_6 is C_1-C_6 alkyl or C_2-C_6 alkylen; or

15 R_5 and R_6 may together form a 5- or 6- membered ring which may contain 1 or 2 heteroatoms selected from N, O or S;

20 R_7 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_4 alkoxy, NR_8 R_9 or 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by one or more of halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl or C_1-C_4 alkoxy;

25 R_8 and R_9 are each independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_4 alkoxy or may together form a 5- or 6- membered ring containing
30 1 or 2 heteroatoms selected from N, O or S;

an enantiomer or a pharmaceutically acceptable salt thereof.

35 A preferred group of therapeutically active compounds of formula I are those wherein R_1 and R_2 are each independently hydrogen, n-propyl, i-propyl or cyclopropyl and R_3 is a carbonylgroup COR_7 . Among these groups are the definition

- of R₇ as alkyl, aminoalkyl e.g. methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, t-butyl and cyclobutyl or aryl, aminoaryl e.g. phenyl, thienyl, fluoro-phenyl and furanyl. Another preferred group is when R₃ is
- 5 aryl e.g. phenyl, thienyl, furanyl, or fluorophenyl. Another preferred group is when R₃ is alkyl e.g. n-propyl, i-propyl or alkenyl e.g. i-propenyl and allyl. Another preferred group of active compounds are those wherein R₄ is halogen in 8 position as well as enantiomers thereof.
- 10 Compounds of formula I wherein R₃ is CN, COOH, COCl, COBr, NH₂, N₃, NO₂ or SO₃CF₃ are new intermediates for preparation of the therapeutically active compounds of formula I.
- 15 C₁-C₆ alkyl in formula I representing straight, branched and cyclic alkyl groups having 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl, i-hexyl, cyclopropyl, cyclobutyl, cyclopentyl,
- 20 cyclohexyl, methylcyclopropyl, ethylcyclopropyl, methylcyclobutyl. Preferred alkyl groups have 1 to 4 carbon atoms.
- C₂-C₆ alkenyl in formula I representing straight or
- 25 branched carbon atoms chains having 2 to 6 carbon atoms and containing one or two double bond, for example allyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, isopentenyl. Preferred alkenyl groups have 2 to 4 carbon atoms and one double bond.
- 30 C₁-C₄ alkoxy in formula I representing a straight alkoxy group having 1 to 4 carbon atoms, for example methoxy, ethoxy, propoxy or butoxy, preferably methoxy and ethoxy.
- 35 C₁-C₄ alkylaryl where aryl may contain 1 or 2 heteroatoms selected from N, O or S in the definition of R₂ in formula I representing an aryl residue having 3 to 12 carbon atoms

in the aromatic ring and optionally 1 or 2 heteroatoms selected from N, O or S in the aromatic ring, bond by a straight or branched alkyl chain having 1 to 4 carbon atoms in the aliphatic chain. The aromatic ring may be substituted by one or more of nitrile, trifluoromethyl, halogen such as fluoro, chloro, bromo, iodo, C₁-C₆ alkyl, e.g. methyl, ethyl, propyl, C₂-C₆ alkenyl e.g. allyl, propenyl, or C₁-C₄ alkoxy preferably in meta and/or para position. Examples of suitable aryl groups in C₁-C₄ alkyl-aryl are phenyl, naphthyl, biphenyl, thienyl, furyl, pyryl, pyrimidyl and pyrrolidinyl. Preferred C₁-C₄ alkylaryl groups are unsubstituted and substituted phenylalkyl groups wherein the alkyl group is a straight or branched alkyl having 1 to 4 carbon atoms and the aromatic ring may be substituted by one or more of fluoro, chloro, bromo, iodo, nitrile, trifluoromethyl, methyl or ethyl in meta and/or para position. For example benzyl, phenethyl and phenylpropyl, especially preferred is phenylpropyl.

20 Halogen in formula I representing fluoro, chloro, bromo, iodo, preferably fluoro, chloro and bromo.

5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and being either (i) optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy or either (ii) fused at two adjacent carbon atoms to an aryl ring, said aryl ring being optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy; in the definition of R₃ in formula I representing either (i) substituted or unsubstituted phenyl, thienyl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, piperazinyl or morpholinyl or either (ii) substituted or unsubstituted quinolyl, isoquinolyl, quinazolyl, quinoxazolyl or indolyl.

5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S in the definition of R₇, R₈ and R₉ in formula I representing phenyl, thienyl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, piperazinyl, morpholinyl.

Examples of suitable 5- or 6-membered ring structures formed by R₁ and R₂ or R₅ and R₆, or R₇ and R₈ respectively and the nitrogen atom and which may contain a further heteroatom selected from N, O or S are piperazine, morpholine, pyrrolidine, pyrrole, pyrroline, imidazole, imidazoline, imidazolidine, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine.

The compounds of the invention have one or two assymmetric carbon atoms. When R is hydrogen the compounds have an assymmetric carbon atom adjacent to the nitrogen atom i.e. C₃ and when R is C₁-C₆ alkyl the compounds have an assymmetric carbon atom adjacent to the nitrogen atom and an assymmetric carbon atom adjacent to the alkyl group i.e. C₄. Thus, the compounds exist as two or four optical isomers i.e. enantiomers. Both the pure enantiomers, racemic mixtures are within the scope of the present invention. The therapeutic properties of the compounds may to a greater or lesser degree be ascribed to the racemate or to the enantiomers occurring.

Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention. Illustrative acids are sulfuric, nitric, phosphoric, oxalic, hydrochloric, formic, hydrobromic, citric, acetic, lactic, tartaric, pamoic, ethanedisulfonic, sulfamic, succinic, methylsulphonic, propionic, glycollic, malic, gluconic, pyruvic, phenylacetic, 4-aminobenzoic, anthranilic, salicylic, 4-amino-


salicylic, 4-hydroxybenzoic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, p-toluenesulfonic, sulfanilic, naphthalenesulfonic, ascorbinic, cyclohexylsulfamic, fumaric, maleic and benzoic acids. These salts are readily prepared by methods known in the art.

Methods of Preparation

10

The compounds of the formula I may be prepared by the following processes constituting a further aspect of the invention.

15 a. Converting a compound of formula II



25


wherein Y is a leaving group such as trifluoromethane sulfonate (OSO_2CF_3), halide e.g. Cl or Br, and X, R, R_1 , R_2 and R_4 are defined as above by substitution of the group Y to a carboxy group COZ, wherein Z is Cl, Br, OH, OR_p where R_p is $\text{C}_1\text{-C}_6$ alkyl to formation of a compound of formula I wherein R_3 is COZ, (IA).

30

The compound of formula II can be converted to the compound of formula IA by the following catalytic cycle. Metal M^0 should be a zerovalent transition metal, such as Pd or Ni with ability to undergo oxidative addition to aryl-Y-bonds e.g. the aryl- SO_3CF_3 bonds. M^0 may be generated in situ

35


from M^{II} . The aryl-CO- M^{II} -Y are formed by treatment with carbon monoxide (CO).



Further reagents are an alcohol such as alkanol e.g. methanol, ethanol, an amine base such as a trialkylamine e.g. triethylamine in an inert organic solvent preferentially a polar aprotic solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetone, acetonitrile etc. The reaction is normally performed at a temperature between +40 to +120°C and at a pressure between 100 to 500 KPa. Optionally followed by hydrolyze and treatment with a thionyl halide e.g. thionylchloride to obtain the corresponding acid halide derivative.

b. Compound of formula I wherein R_3 is COZ (IA) can also be formed by the reversed process:


A reaction as the catalytic cycle using a zerovalent transition metal M^0 , such as Pd, or Ni with ability to
 5 undergo an oxidation addition to Z-Y, wherein Z is defined Cl, Br, OH or OR_p where R_p is C_1-C_6 alkyl and Y is a leaving group such as SO_3CF_3 and halide, treatment with carbon monoxide followed by addition of a compound of
 10 formula III, wherein X, R, R_1 , R_2 and R_4 are as defined under formula I.



30

The $Z-CO-M^{II}-Y$ can also be formed from $Z-COCl$ directly. The reaction conditions and reagent are the same as described in method a. above. Hydrolyze of suitable carboxylic acid ester forms the free acid, which can be converted to its acid halide derivative.
 35

c. Converting a compound of formula II




II

IB

10 wherein X, R, R₁, R₂ and R₄ are as defined above and Y is
 a leaving group such as Cl, Br or SO₃CF₃ by treatment with
 a cyanide reagent such as copper cyanide (CuCN) to obtain
 a compound of formula I wherein R₃ is CN. The reaction with
 cyanide reagent is performed in an inert organic solvent
 15 such as dimethylformamide, hexamethylenephosphotriamide
 etc. at a temperature between 20° to 200°C preferably
 between 50° to 150°C and at normal temperature.

d. Amination of a compound of formula IA

20



30

IA

IC


wherein X, R, R₁, R₂ and R₄ are as defined above and Z is
 Cl, Br, OH or OR_p where R_p is C₁-C₆ alkyl.

35 If the compound of formula IA is a carboxylic acid ester
 it must first be hydrolyzed to form the free acid. The
 free acid is then transformed into the amide IC via its

acid chloride derivative by reaction of the corresponding amine NR_8R_9 , where R_8 and R_9 are as defined under formula I, in a nonpolar aprotic solvent e.g. toluene, benzen at reflux temperature between 0 to 100°C.

5

e. Wittig reaction to formation of a compound of formula I where R_3 is a $\text{C}_2\text{-C}_6$ alkenyl group (IE),



20 A 5-carboxy chroman/thiochroman derivative, where X, R, R_1 , R_2 and R_4 are defined as above and R_7 is alkyl defined as above (ID) is converted by using a dipolar reagent such as alkyltriphenylphosphonium halide to formation of a corresponding alkenyl group (IE).

25

f. Catalytic hydrogenation of a 5-alkene chroman/thiochroman derivative of formula I wherein R_3 is a $\text{C}_2\text{-C}_6$ alkenyl group by using H_2/Pd , H_2/Pt or $\text{H}_2/\text{Raney Ni}$ to formation of corresponding chroman/thiochroman derivative

30 of formula I wherein R_3 is $\text{C}_1\text{-C}_6$ alkyl (IF).


g. Substitution of a 5-bromo-chroman/thiochroman derivative by treatment with an appropriate stannic tri-alkyl reagent in presence of a zerovalent metal preferably

35 palladium (Pd^0) to obtain a compound of formula I wherein R_3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_4$ alkenyl or aryl, in presence of carbonmonoxide (CO) is formed a compound of formula I


wherein R_3 is COR_7 wherein R_7 is C_1-C_6 alkyl, C_2-C_6 alkylen or aryl.

The substitution may be performed by one of the following
5 ways:

1)




20 2)



SUBSTITUTE SHEET

h. Converting the 5-carboxy chroman/thiochroman derivative of formula I




15

where X, R, R₁, R₂ and R₄ are defined as above and Z is Cl, Br by using R₇Li wherein R₇ is alkyl, alkenyl or aryl as a cuprate reagent to obtain corresponding 5-keto-chroman/thiochroman derivative. Suitable R₇Li used is

20 alkyl lithium e.g. CH₃Li, alkenyllithium e.g. CH₂CHLi or aryllithium e.g. phenyl-Li. The reaction is performed in an inert organic solvent preferably a nonpolar aprotic solvent such as ethers e.g. diethyl ether, tetrahydrofuran at a temperature between -50° - +50°C.

25

i. Hydrolysis of a compound of formula I, wherein R₃ is CN (IB)



IB


IA

SUBSTITUTE SHEET

wherein X, R, R₁, R₂ and R₄ are as defined above optionally followed by treatment with a thionyl halide e.g. thionylchloride, thionylbromide to obtain a compound of formula I
 5 wherein R₃ is COZ where Z is OH, Cl or Br.

j. Substitution of a compound of formula I, wherein R₃ is CN (IB)

10



20

IB


ID

wherein X, R, R₁, R₂ and R₄ are defined as above by treatment with an appropriate organometallic reagent preferentially an organolithium such as R₇Li or a Grignard reagent such as R₇Mg halide in an inert organic solvent preferentially a nonpolar aprotic solvent such as bensen, ethers e.g. diethylether, tetrahydrofuran followed by hydrolysis of the intermediate complex to obtain a compound
 25 of formula I wherein R₃ is COR₇ where R₇ is C₁-C₆ alkyl, C₂-C₆ alkenyl or aryl.

k. Hydrogenation of a 5-alkene thiochroman/chroman derivative of formula I wherein R₃ is a C₂-C₆ alkenyl group
 35 by using H₂/Pd, H₂/Pt or H₂/Raney Ni or potassium azodicarboxylate to formation of corresponding thiochroman/chroman derivative of formula I wherein R₃ is C₁-C₆ alkyl.

SUBSTITUTE SHEET

1. Converting a compound of the formula (II)



wherein Y is a leaving group such as trifluoromethanesulphonate (Tf), phosphonate, halide such as Br or J and R, R₁ and R₂ are defined as above by substitution of the group Y to R₃ where R₃ is a C₂-C₆ alkenyl group (IE).

15


The compound (II) may be converted to (IE) by reaction with a transition metal, such as Pd or Ni with ability to form ligand complex and undergo oxidative addition. A suitable alkenyl-substituent can be introduced via a suitable tri-alkylalkenylstannane.

20

Further reagents are an amine such as triethylamine and lithiumsalt e.g. lithium chloride. The reaction is preferentially carried out in a polar aprotic solvent such as dimethylformamide, dioxane, acetonitril or dimethylsulfoxide at a temperature between +40 to +120°C.

25

m. Converting a compound of the formula (II)




wherein Y is a leaving group such as trifluoromethanesulphonate (Tf), phosphonate, halide such as Br or J and R, R₁ and R₂ are defined as above by substitution of the group Y to 5- or 6-membered aryl (Ar) which may contain 1 or 2
 5 heteroatoms selected from N, O, or S being either substituted or fused at two adjacent carbon atoms to an aryl ring as defined above to formation of a compound of formula IF.

The compound (II) may be converted to (IF) by reaction with
 10 a transition metal, such as Pd or Ni with ability to form ligand complex and undergo oxidative addition. A suitable aryl-substituent can be introduced via a suitable trialkyl-arylstannane or aryl-boric acid reagents.

Further reagents are an amine such as triethylamine and
 15 lithiumsalt e.g. lithium chloride. The reaction is preferentially carried out in a polar aprotic solvent such as dimethylformamide, dioxane, acetonitril or dimethylsulfoxide at a temperature between +40 to +120°C.

20 The following method describes one way of obtaining the intermediate of formula IB



wherein R_1 , R^2 and R^4 are defined as in formula I

Pharmaceutical preparations

- 5 According to the present invention the compounds of the formula I will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutically acceptable non-toxic acid addition salt,
- 10 e.g. the hydrochloride, hydrobromide, lactate, acetate, phosphate, sulphate, sulphamate, citrate, tartrate, oxalate and the like in a pharmaceutically acceptable dosage form. The dosage form may be a solid, semisolid or liquid preparation. Usually the active substance will constitute between
- 15 0.1 and 99% by weight of the preparation, more specifically between 0.5 and 20% by weight for preparations intended for injection and between 0.2 and 50% by weight for preparations suitable for oral administration.
- 20 To produce pharmaceutical preparations containing a compound of the formula I in the form of dosage units for oral application, the selected compound may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin,
- 25 cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be
- 30 coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the table can be coated with a polymer known to the man skilled in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents.
- 35 Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.

For the preparation of soft gelatine capsules, the active substance may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the active substance using either the abovementioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.

Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing from about 0.2% to about 20% by weight of the active substance herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl-cellulose as a thickening agent or other excipients known to the man in the art.

Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.

Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.01-100 mg/kg

bodyweight at peroral administration and 0.001-100 mg/kg bodyweight at parenteral administration.

Working examples

- 5 The following examples will further illustrate the invention.

Example 1

3-Dipropylamino-5-trifluoromethanesulfonylchroman

10

3-Dipropylamino-5-hydroxychroman (Thorberg et al. Acta Pharm. Suec. 24(1987)) (1.4 g, 4.0 mmol) and N,N-dimethylamino-pyridine (0.1 g, 0.75 mmol) were dissolved in 50 mL methylene dichloride (CH_2Cl_2) and cooled to -30°C . 2,4,6-Collidine
15 (0.75 mL, 5.7 mmol) was added followed by trifluoromethane sulfonic anhydride (1.0 mL, 6.0 mmol). The solution was stirred at -20°C for 3 hours and then allowed to reach ambient temperature. The solution was washed with aqueous NaHCO_3 , dried with Na_2SO_4 and evaporated to dryness. The
20 pale yellow oil was finally purified by flash chromatography (silica gel) by elution with ethyl acetate/hexane 1:9. Yield: 55%, Mp $125-127^\circ\text{C}$ (oxalate).

Example 2

25 3-Dipropylamino-5-methyloxycarbonylchroman

3-Dipropylamino-5-trifluoromethanesulfonylchroman (Example 1; 4.43 g, 11.6 mmol) was dissolved in 80 mL dimethylformamide/methanol 6:2 and the solution was degassed (10 mm Hg,
30 20°C , 15 min). PdOAc_2 (76 mg, 0.34 mmol), 1,3-bis-diphenylphosphinopropane (141 mg, 0.34 mmol) and triethylamine (3.5 mL, 25 mmol) were then added. The mixture was heated to 70°C under CO atmosphere and stirred for 5 hours. The solution was cooled, diluted with toluene (200 mL), washed with
35 aqueous NaHCO_3 , dried with Na_2SO_4 and evaporated to dryness. The oil was purified by flash chromatography (silica gel) by elution with ethyl acetate/hexane 1:8.

Yield: 76%, Mp 150-152°C (HCl-salt).

Example 3

3-Dipropylamino-5-carbamoylchroman

5

3-Dipropylamino-5-methyloxychroman (Example 2; 400 mg, 1.37 mmol) was dissolved in 10 ml methanol and NaOH (60 mg, 1.5 mmol) in 2 mL H₂O was added. The mixture was refluxed for 5 hours, cooled, filtered through Celite" and evaporated to
10 dryness. The residue was refluxed in SOCl₂ (5 mL, 68 mmol) for 30 minutes. The excess SOCl₂ was then removed in vacuo to give 3-dipropylamino-5-chloroformylchroman*HCL as a gum. The pale brown gum was dissolved in CH₂Cl₂ (50 mL), and a stream of NH₃ (g) was introduced during 2 minutes. The
15 solution was washed with aqueous NaHCO₃, dried with Na₂SO₄ and evaporated to dryness. The oil was purified by flash chromatography (silica gel) by elution with ethyl acetate-
/hexane 1:4. Yield 80%, ¹³C-NMR: 172.0 154.9 136.5 126.9
120.4 119.1 118.6 67.8 53.0 52.6 26.1 22.4 21.9 14.1 11.7.

20

Example 4

3-dipropylamino-5-N,N-dimethylcarbamoylchroman

The title compound was prepared analogous to the procedure
25 used in Example 3 starting from 3-dipropylamino-5-methyl-oxycarbonylchroman and substituting dimethylamine (g) in place of NH₃ (g). ¹³C-NMR: 189.3 170.3 149.9 137.4 126.7
126.1 124.9 65.8 64.7 48.2 47.7 30.7 26.0 15.1 10.9.

30 Example 5

3-Dipropylamino-5-N,N-diisopropylcarbamoylchroman

The title compound was prepared analogous to the procedure
used in Example 3 starting from 3-dipropylamino-5-methyloxy-
35 chroman. Mp 228-230°C (HCl-salt).

Example 63-Dipropylamino-5-N-methylcarbamoylchroman

The title compound was prepared analogous to the procedure used in Example 3 starting from 3-dipropylamino-5-methyloxycarbonylchroman and substituting methylamine (g) in place of NH₃ (g). Mp 95-97°C (oxalate).

Example 710 3-Dipropylamino-5-acetylchroman

3-Dipropylamino-5-chloroformylchroman*HCl (4.42 g, 13.4 mmol), prepared from 3-dipropylamino-5-methyloxycarbonylchroman (Example 2) analogous to the procedure used in Example 3, in dry tetrahydrofuran (20 ml), was added to a pre-formed solution of lithium dimethylcuprate; prepared from MeLi and CuI, in 200 mL tetrahydrofuran at -78°C. The solution was stirred for 15 minutes at -78°C and was then allowed to reach room temperature during 10 minutes. Then, 30 mL H₂O was slowly added. The organic phase was decanted, dried with Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography (silica gel) by elution with ethyl acetate/hexane 1:8. The title compound was crystallized as salt from ethyl acetate. Mp 106-108°C (oxalate).

Example 83-Dipropylamino-5-cyclopropylcarbonylchroman

30 The title compound was prepared analogous to the procedure used in Example 7 substituting lithium dicyclopropylcuprate (J. Org. Chem., 41 (22), 1976) in place of lithium dimethylcuprate. Mp 100-102°C (oxalate).

35 Example 93-Dipropylamino-5-tertbutylcarbonylchroman

The title compound was prepared analogous to the procedure used in Example 7 substituting lithium di-tertbutylcuprate (from tertbutyllithium and $\text{CuBr}\cdot\text{Me}_2\text{S}$) in place of lithium dimethylcuprate. Mp 118-120°C (oxalate).

5

Example 10

3-Dipropylamino-5-isopropylcarbonylchroman

The title compound was prepared analogous to the procedure used in Example 7 substituting magnesium diisopropylcuprate (from isopropylmagnesium chloride and $\text{CuBr}\cdot\text{Me}_2\text{S}$) in place of lithium dimethylcuprate. Mp 60-62°C (oxalate).

10

Example 11

15 3-Dipropylamino-5-(4-fluorophenylcarbonyl)chroman

The title compound was prepared analogous to the procedure in Example 7, substituting magnesiumdi(4-fluorophenyl)cuprate (from 4-fluorophenyl magnesium bromide and CuI) in place of lithium dimethylcuprate. Mp 98.3-98.4°C (oxalate).

20

Example 12

3-Dipropylamino-5-(2-thienylcarbonyl)chroman

25 The title compound was prepared analogous to the procedure used in Example 7 substituting lithium di(2-thienyl)cuprate (from 2-thienyllithium and CuI) in place of lithium dimethylcuprate. Mp 87-88.5 (oxalate).

30 Example 13

3-Dipropylamino-5-isopropenylchroman

Methyltriphenylphosphoniumbromide (0.62 g, 1.74 mmol) was dissolved in dry ethyl ether (20 ml) under nitrogen at ambient temperature and n-BuLi (0.7 ml, 2.5 M, 1.74 mmol) was added and the solution was stirred for 4 hours.

35

3-Dipropylamino-5-acetylchroman (Example 7; 0.40 g, 1.45

mmol) was dissolved in dry diethyl ether (2.0 ml) and this solution was added to the previously formed Wittig-reagent. The mixture was stirred at ambient temperature overnight. The solution was diluted with toluene and washed with water. 5 Drying of the organic phase with Na₂SO₄ and evaporation to dryness gave a solid, which was finally purified by flash chromatography by elution with ethyl acetate/hexane 1:4. The collected fractions were evaporated and gave the title compound as a colourless oil. ¹³C-NMR: 11.82 21.94 24.28 10 26.69 52.79 53.64 67.70 115.03 115.13 118.73 120.07 126.83 144.88 145.27 154.03.

Example 14

3-Dipropylamino-5-aminochroman

15

3-Dipropylamino-5-methyloxycarbonylchroman (Example 2; 1.0 g, 3.4 mmol) was dissolved in methanol (20 ml). Sodium hydroxide (0.16 g, 4.1 mmol) in water (1.0 ml) was added and the solution was refluxed with nitrogen overnight. The 20 solution was evaporated to dryness, toluene (20 ml) was added and again the solution was evaporated to dryness. The residue was dissolved in toluene 20 ml, diphenylphosphoryl azid (1.87 g, 6.8 mmol) was added and the solution was refluxed for 2 hours. Methanol (2.0 ml) was added and reflux 25 was continued for 4 hours. The solution was cooled, washed with water and extracted with dilute HCl (aq.). The acidic water phase was neutralized NaOH (aq.) and extracted with toluene. The toluene-phase was dried with sodium sulphate and evaporated to dryness. The residue was dissolved in 30 ethanol containing 10% NaOH (20 ml) and the solution was refluxed overnight. The solution was cooled and diluted with toluene. Washing with water, drying of the organic phase and evaporation to dryness afforded the title compound as an oil, which was converted to a dihydrochloride salt. Mp 173- 35 174°C.

Example 153-Dipropylamino-5-nitrochroman

3-Dipropylamino-5-aminochroman (Example 14; 0.050 g, 0.20
5 mmol) was dissolved in a mixture of trifluoroacetic acid
(0.080 ml, 1.0 mmol) in water (5 ml). The clear solution was
cooled to 0-4°C. Sodium nitrite (0.017 g, 2.5 mmol) in water
(1.0 ml), was added dropwise with good stirring. The solution
was stirred for 15 minutes and neutralized with calcium
10 carbonate. A solution of sodium nitrite (0.50 g, 7.2 mmol)
in water (1.0 ml) was added followed by a mixture of copper
sulfate (0.10 g, 0.62 mmol) and copper (I) oxide in water
(1.0 ml). The solution was stirred at 0°C for 20 minutes and
then at ambient temperature for 2 hours. The solution was
15 extracted with diethyl ether. The organic phase was dried
with sodium sulfate and evaporated to dryness. The residue
was purified by flash chromatography on silica gel by elution
with ethyl acetate/hexane 1:9 to give the title compound. Mp
150-151°C (hydrochloride).

20

Example 163-Dipropylamino-5-azidochroman

3-Dipropylamino-5-aminochroman (Example 14; 0.050 g, 0.20
25 mmol) was diazotized according to the procedure of Example
15. After stirring for 15 minutes, sodium azide (0.026 g,
0.4 mmol) in water (1.0 ml) was added. After stirring at 5°C
overnight the solution was worked-up and purified according
to the procedure of Example 15 to give the title compound.
30 Mp 167-168°C (oxalate).

Example 173-Dipropylamino-5-(pyrrol-1-yl)chroman

35 3-Dipropylamino-5-aminochroman (Example 14; 0.60 g, 2.42
mmol) was dissolved in acetic acid (10 ml) and 2,5-dimethoxy-
tetrahydrofuran (0.40 g, 3.0 mmol) was added. The solution

was refluxed for 1 hour. The solution was neutralized with NaOH (aq.) and extracted with toluene. The organic phase was dried with sodium sulfate and evaporated to dryness. The residue was purified by flash chromatography on silica gel
5 by elution with ethyl acetate/hexane 1:9 to give the title compound. ¹³C-NMR: 111.75 21.89 24.81 52.69 53.15 67.94 108.93 115.67 118.22 118.44 121.87 127.22 141.47 155.27

Example 18

10 3-(Methyl(3-phenylpropyl)amino)-5-hydroxychroman

3-Amino-5-methoxychroman (Thorberg et al. Acta Pharm. Suec. 24(1987)) (2.0 g, 9.28 mmol) was dissolved in methanol (50 ml) and pH was adjusted to 6.0 with acetic acid. The solution
15 was cooled to 0°C and sodium cyanoborohydrid (0.87 g, 13.8 mmol) was added together with 3-phenylpropanal (1.22 ml, 9.28 mmol), the cooling was withdrawn and the solution was stirred at ambient temperature for 4 hours. Paraformaldehyde (0.42 g, 14 mmol) and sodium cyanoborohydride (0.87 g, 9.28
20 mmol) was added and stirring was continued overnight at ambient temperature. The solution was diluted with toluene and washed with water. Drying with sodium sulfate and evaporation to dryness gives an oil. The oil was purified by flash chromatography on silica gel by elution with
25 ethylacetate/hexane 1:4. The collected fractions were evaporated to give an oil. The oil was treated with HBr (47% aq.) at 120°C for 1 hour. The solution was cooled and neutralised with sodium hydroxide and extracted with toluene. The organic phase was dried and evaporated to give the title
30 compound as an oil. ¹³C-NMR: 22.502 29.09 33.47 38.19 53.66 67.75 102.04 109.20 110.46 125.78 127.05 128.36 142.20 155.29 158.28.

Example 19

35 3-(methyl(3-phenylpropyl))amino-5-methyloxycarbonylchroman

3-(methyl(3-phenylpropyl))amino-5-hydroxychroman (Example

18; 1.0 g, 3.37 mmol) was dissolved in CH_2Cl_2 (20 ml) at -20°C . Pyridine (0.32 ml, 4 mmol), trifluoromethanesulfonic anhydride (0.65 ml, 5.9 mmol) and dimethylaminopyridine (DMAP), (0.041 g, 0.59 mmol) was added at -20°C under
5 nitrogen. The solution was stirred for 3 hours at -20°C . Cooling was withdrawn and the solution was diluted with toluene, washed with sodium hydrogen carbonate (aq.), dried with sodium sulfate, filtered through silica gel and evaporated to dryness. The remaining oil was dissolved in 13
10 ml degassed methanol/DMF 3:10. Palladium acetate (0.056 g, 0.25 mmol), 1,3-bis(diphenylphosphino)propane (0.103 g, 0.25 mmol) and triethyl amine (0.76 ml, 5 mmol) was added and the solution was flushed with $\text{CO}(\text{g})$ under vigorous stirring. The pressure in the reaction vessel was raised to 20.2 KPa(e)
15 with the aid of a $\text{CO}(\text{g})$ -cylinder fitted with a regulator. Stirring was continued overnight at 75°C . The pressure and temperature was normalized and the solution was diluted with toluene and washed with water. The organic phase was dried and evaporated to dryness. The remaining oil was purified by
20 flash chromatography on silica gel by elution with ethyl acetate/hexane 1:4. The collected fractions were evaporated to give the title compound as a colourless oil. ^{13}C -NMR:
26.88 29.00 33.20 37.85 51.64 53.37 55.44 67.24 120.60 123.06
123.40 125.59 126.47 128.17 128.24 130.36 142.01 154.93
25 167.29.

Example 20

3-(methyl(3-phenylpropyl))amino-5-N-methylcarbamoyl chroman

30 3-(methyl(3-phenylpropyl))amino-5-methyloxycarbonylchroman (Example 19; 0.32 g, 0.94 mmol) was dissolved in methanol (10 ml). NaOH (0.08 g, 2 mmol) in 1 ml water was added and the solution was refluxed overnight under nitrogen. The solution was evaporated to dryness and co-evaporated with
35 toluene (10 ml) to dryness again. The remaining solid was refluxed in SOCl_2 for 30 minutes and evaporated to dryness. The pale brown gum was dissolved in tetrahydrofuran (THF) 20

ml and treated with methyl amine (g) for 1 minute under vigorous stirring. The solution was diluted with toluene and washed with sodium hydrogencarbonate (aq.). Drying and evaporation gave a gum, which was finally purified by flash chromatography on silica gel by elution with ethyl acetate-
5 /hexane 1:2. The collected fractions were evaporated to give the title compound as a colourless gum. Crystallization from ethyl acetate as oxalate gave white needles. Mp 150-151°C. (oxalate).

10

Example 213-Dipropylamino-5-trifluoromethanesulfonylthiochroman

3-Dipropylamino-5-hydroxybenzothiopyran (EP 0222 996;
15 420 mg, 1.58 mmol) and collidine (0.27 g, 0.29 mL) were dissolved in 15 mL of CH_2Cl_2 and cooled to -30°C . Trifluoromethanesulfonic anhydride (0.54 g, 0.32 mL) was added dropwise and allowed to reach ambient temperature, and after 20 minutes diluted with methylenedichloride.
20 The solution was washed with saturated NaHCO_3 , dried with Na_2SO_4 , and evaporated in vacuo. Chromatography on silica by elution with CHCl_3 gave 0.62 g of the title compound as the base. Yield: 98%. Mp. $37-8^\circ\text{C}$; ^{13}C NMR (200 MHz- CDCl_3) PPM 148.3, 136.7, 128.4, 127.2,
25 126.3, 122.0, 117.1, 115.2, 55.6, 52.5, 28.0, 26.6, -22.6, 11.8.

Example 223-Dipropylamino-5-methyloxycarbonylthiochroman

30

3-Dipropylamino-5-hydroxybenzothiopyran (EP 0222 996;
620 mg, 1.6 mmol) was dissolved in 11 mL of dimethylformamide/methanol (6:2) and the solution was degassed (10 mm, 22°C , 15 min). $\text{Pd}(\text{OAc})_2$ (11mg), 1,3-bis-diphenyl-
35 phosphinopropane (19 mg), and triethylamine (0.48 mL, 0.35 g) were added to the reaction mixture.

The mixture was heated to 70°C under carbonmonoxide atmosphere and stirred for 5 hours.

The solution was cooled, diluted with 30 mL of toluene, washed with saturated NaHCO_3 , dried with Na_2SO_4 , and
5 evaporated in vacuo.

Chromatography on silica by elution using a gradient CHCl_3 -> 10% EtOAc/ CHCl_3 gave 310 mg of the title compound (base) as a slightly yellow oil; Yield: 64%. ^{13}C NMR (200 MHz- CDCl_3)
PPM 168.2, 136.6, 134.8, 131.6, 130.1, 126.5, 125.7, 56.7,
10 52.5, 52.1, 30.4, 28.0, 22.3, 11.9.

Example 23

3-Dipropylamino-5-acetylthiochroman

15 3-Dipropylamino-5-methyloxycarbonylthiochroman
(Example 22; 310 mg, 1.01 mmol) was dissolved in 8 mL methanol and 60 mg of sodium hydroxide in 2 mL water was added. After 5 hours reflux the mixture was cooled and evaporated in vacuo. The residue was dissolved in thionylchloride (5
20 ml) and refluxed for 1 hour. The excess thionylchloride was evaporated in vacuo to obtain a gum.

The residual gum was dissolved in a minimal amount of tetrahydrofuran and added dropwise to a cooled (-78°C) solution of lithium dimethyl cuprate (2.02 mmol) in 20 mL of tetra-
25 hydrofuran.

The reaction mixture was stirred for 15 minutes at -78°C, then allowed to reach ambient temperature and after 10 minutes the reaction was quenched with 0.9 mL of water. The reaction was filtered through Celite[®] and evaporated to
30 dryness.

The residue were dissolved in ether, washed with saturated NaHCO_3 , treated with brine, dried with Na_2SO_4 , and evaporated in vacuo to afford the crude base as an oil.

The crude residue was chromatographed on silica by elution
35 using a gradient of CHCl_3 -> 5% EtOAc/ CHCl_3 .

The hydrochloride salt was obtained by dissolving the pure base in ether and dropping an excess of an ethereal HCl

solution. Recrystallization in trichloromethane/diethylether gave 92 mg of the title compound as a white solid; Yield: 27%. Mp 141-2°C; ^{13}C NMR (200 MHz- CDCl_3) PPM 201.9, 138.4, 135.9, 131.7, 131.2, 127.2, 127.0, 59.9, 54.1, 51.8, 29.9, 27.9, 26.1, 18.6, 18.2, 11.6.

Example 24

5-Allyl-3-(dipropylamino)thiochroman

10 To a solution of 3-(dipropylamino)-5-trifluoromethane-sulfonylthiochroman (Example 21; 1.28 g, 3.22 mmol), tetra-
kis(triphenylphosphine)palladium(0) (76 mg, 0.064 mmol) and
a few crystals of 2,6-di-*t*-butyl-4-methylphenol in 10 mL
anhydrous toluene was 1.17 g (1.1 mL, 3.53 mmol) tributyl-
15 allyltin added neat. The resulting solution was refluxed for
4 hours then pyridine (1 mL) was added to the cooled solution
followed by 2.1 ml of a hydrogen fluoride-pyridine complex
(Stille J.K. et al. JOC 52(1987) 422).

After stirring for 1 hour at room temperature, the reaction
20 mixture was diluted with 50 ml diethyl ether and treated,
successively, with 50 mL 1 M NaOH solution, H_2O (x2), washed
with a saturated NaCl solution and dried (NaSO_4). After
filtering and removal of the solvent in vacuo, the crude was
obtained as a dark oil.

25 Chromatography on silica by elution using a gradient hexane
-> 5% EtOAc/hexane gave 0.85 g of the title compound (base)
as a slightly yellow oil. Yield: 91%. ^{13}C NMR: (200
MHz- CDCl_3) PPM 139.0, 136.5, 134.0, 133.0, 126.1, 125.9,
125.0, 116.0, 57.0, 52.6, 37.7, 29.5, 27.7, 22.5, 11.9.

30 A portion of the base was taken out and made into the hydro-
chloride salt by dissolving the pure base in ether and
dropping an excess of an ethereal HCl solution. Recrystal-
lizing (AcCN-Et20-hexane) gave a white solid. Mp 164-5°C.

35 Example 25

3-(Dipropylamine)-5-propylthiochroman hydrochloride

To a stirred suspension of potassium azodicarboxylate (0.76 g, 3.9 mmol) (made fresh from diethyl azocarboxylate and potassium hydroxide) and 5-allyl-3-(N,N-dipropylamino)-thiochroman (Example 24; 0.4 g, 1.4 mmol) in 10 mL anhydrous methanol was added a solution of glacial acetic acid/methanol (1:4) until the yellow color (from the potassium salt) disappeared.

After 30 min stirring at room temperature more potassium azodicarboxylate (200 mg) was added and again decomposed as before. This process was continued until analysis (GC) showed no starting material remaining.

Upon completion, (2 hours and 4 additions of the potassium salt) the solvent was removed in vacuo. To the remains, a 2 M NaOH solution was added which was extracted (x2) with diethyl ether and the combined organic portions were treated with a saturated NaCl solution, and dried (Na_2SO_4). The crude base was obtained as a light colored oil upon the removal of the solvent in vacuo.

Chromatography on silica by elution using a gradient hexane - 5% EtOAc/hexane gave the title compound (base) as a clear oil. The hydrochloride salt was made by dissolving the pure base in ether and dropping and an excess of an ethereal HCl solution. Recrystallizing (chloroform-Et₂O) gave 0.30 g of a white solid. Yield: 66%. Mp 150-151°C. ¹³C NMR: (on base, 200 MHz-CDCl₃) PPM 141.6 133.7 132.8, 125.8, 125.6, 124.5, 57.1, 52.6, 35.3, 29.5, 27.6, 23.6, 22.4, 14.3, 11.9.

Pharmacology

Pharmacological treatment of depression in man

Evidence is available that in depressed patients the neurotransmission in the central nervous system (CNS) may be disturbed. These disturbances appear to involve the neurotransmitters noradrenaline (NA) and 5-hydroxytryptamine (5-HT). The drugs most frequently used in the treatment of depression are considered to act by improving the neurotransmission of either or both of these physiological

agonists. Available data suggest that the enhancement of 5-HT neurotransmission will primarily improve the depressed mood and anxiety, whereas the enhancement of noradrenaline neurotransmission will rather improve the retardation
5 symptoms occurring in depressed patients. In recent years many efforts have been made to develop new drugs with high selectivity for the improvement of the 5-HT neurotransmission in the CNS.

10 The mechanism of action for the drugs generally used today in the therapy of mental depression is indirect, i.e. they act by blocking the reuptake of the neurotransmitters (NA and/or 5-HT) released from nerve terminals in the CNS, thus
15 synaptic cleft and hence restoring an adequate neurotransmission.

A fundamentally different way to improve the neurotransmission in the central 5-HT-neurons would be to use a direct
20 5-HT-receptor agonist. In order to minimize side effects, a high selectivity for this kind of receptors would then be preferable.

Antagonisms of the inhibitory autoreceptors located on the
25 cellbodies of 5-HT-neurons would be another fundamentally different way to improve the 5-HT neurotransmission.

Surprisingly, we have found that a group of compounds of the formula I have selective, direct stimulating or inhibitory
30 effect on a subgroup of central 5-HT receptors. Another observation is that some of those compounds have a particularly good oral bioavailability. In order to evaluate the 5-HT-receptor stimulating effect and selectivity, the affinity for various receptors in rat brain were measured in
35 vitro using receptor assays (K_i nM).

In vitro test: Receptor binding assay

5HT_{1A} binding assay. Cerebral cortex + hippocampus from each rat was dissected and homogenized in 15 ml ice-cold 50 mM Tris-HCl buffer 4.0 mM CaCl₂ and 5.7 mM ascorbic acid, pH 7.5 with an Ultra-Turrax (Janke & Kunkel, Staufen, FRG) for ten s. After centrifugation for 12.5 min at 17,000 rpm (39,800 x g in a Beckman centrifuge with a chilled JA-17 rotor (Beckman, Palo Alto, CA, USA), the pellets were re-suspended in the same buffer and homogenization and centrifugation repeated. To each pellet 5 ml ice-cold 0.32 M sucrose were added and homogenized for 5 sec. These samples were kept frozen at -70°C. When used they were diluted with the buffer to 8 mg tissue/ml and homogenized for 10 sec. The tissue homogenates were incubated for ten minutes at 37°C and then supplied with 10 µM pargyline followed by reincubation for 10 minutes.


The binding assay followed that described by Peroutka, J. Neurochem. 47, 529-540, (1986). The incubation mixture (2 ml) contained ³H-8-OH-DPAT (0.25 to 8 nM), 5 mg/ml tissue homogenate in 50 mM Tris-HCl buffer containing 4.0 mM CaCl₂ and 5.7 mM ascorbic acid, pH 7.5. Six different concentrations of ³H-8-OH-DPAT were analyzed. Binding experiments were started by the addition of tissue homogenate and followed by incubation at 37°C for 10 minutes. The incubation mixtures were filtered through Whatman GF/B glass filters with Brandel Cell Harvester (Gaithersburg, MD, USA). The filters were washed twice with 5 ml ice-cold 50mM Tris-HCl buffer, pH 7.5, and counted with 5 ml Ready-solv HP (Beckman) in a Beckman LS 3801 scintillation counter. Non-specific binding was measured by the addition of 10 µM 5-HT to the reaction mixture. The binding data was processed by non-linear least squares computer analysis (Munson and Rodbard, Anal. Biochem. 107, 220-239, (1980).

The test results are expressed as K_i and are given in nM. For instance, 3-dipropylamino-5-acetylchroman has K_i 1,0 (nM), 3-dipropylamino-5-carbamoylchroman has K_i 3,1 (nM), 3-dipropylamino-5-N-methylcarbamoylchroman has K_i 3,3 5 (nM) and 3-dipropylamino-5-(2-thienylcarbonylchroman has K_i 1,7 (nM).

Claims

1. A compound of the formula

5



(I)

10

wherein

15 X is O or S;
 $\begin{matrix} \text{(O)} \\ \parallel \\ \text{P} \end{matrix}$

p is an integer 0, 1 or 2;

20

R is hydrogen, fluoro or C₁-C₆ alkyl;

R₁ is hydrogen, C₁-C₆ alkyl or C₂-C₆ alkenyl;

25

R₂ is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkylaryl where aryl may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy; or

30

R₁ and R₂ may together form a 5- or 6- membered ring which may contain 1 or 2 heteroatoms selected from N, O or S;

35

R₃ is halogen, CN, CF₃, SO₃CF₃, N₃, NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, NH₂, NR₅R₆, COR₇, 5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and being either (i) optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl,

5 C₂-C₆ alkenyl or C₁-C₄ alkoxy or either (ii) fused at two adjacent carbon atoms to an aryl ring, said aryl ring being optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy;

R₄ is hydrogen, C₁-C₆ alkyl or halogen;

10 R₅ is hydrogen C₁-C₆ alkyl or C₂-C₆ alkenyl;

R₆ is C₁-C₆ alkyl or C₂-C₆ alkenyl; or

15 R₅ and R₆ may together form a 5- or 6-membered ring which may contain 1 or 2 heteroatoms selected from N, O or S;

20 R₇ is hydrogen, hydroxy, chloro, bromo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkoxy, NR₈ R₉ or 5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by one or more of halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₁-C₄ alkoxy;

25 R₈ and R₉ are each independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkoxy or may
30 together form a 5- or 6- membered ring containing 1 or 2 heteroatoms selected from N, O or S;

an enantiomer or a salt thereof.

35 2. A compound according to claim 1 wherein X is O.

3. A compound according to claim 1 wherein

$$\begin{array}{c} \text{(O)}_p \\ \parallel \\ \text{S} \end{array}$$
 X is S and p is 0, 1 or 2.

5

4. A compound according to claim 1 wherein

$$\begin{array}{c} \text{(O)}_p \\ \parallel \\ \text{S} \end{array}$$
 X is S and p, R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ are defined as in claim 1 with the proviso that when R is hydrogen or C₁-C₆ alkyl then R₃ cannot be halogen or C₁-C₆ alkyl.

10

15 5. A compound according to claim 1 wherein X is

$$\begin{array}{c} \text{(O)}_p \\ \parallel \\ \text{S} \end{array}$$
 S and p is 0, R₁ and R₄ is hydrogen, R and R₂ are propyl with the proviso that R₃ cannot be propyl.

20

6. A compound according to any of claims 1, 2, 3, 4 or 5 wherein R₃ is halogen, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, NR₅ R₆, COR₇, 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and being either

25 (i) optionally substituted by one or more substituents independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy or either (ii) fused at two adjacent carbon atoms to an aryl ring, said aryl ring being optionally substituted by one or more substituents

30 independently selected from halogen, CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl or C₁-C₄ alkoxy; R₇ is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₄ alkoxy, NR₈ R₉ or 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by one or more of halogen,

35 CN, CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₁-C₄ alkoxy; X, P, R, R₁, R₂, R₄, R₅, R₆, R₈ and R₉ are defined as in claim 1, an enantiomer or a pharmaceutically acceptable salt thereof for use in therapy.

40 7. A compound according to any of claims 1-6, wherein R₁

and R_2 are the same or different and selected from hydrogen, n-propyl, i-propyl and cyclopropyl.

8. A compound according to any of claims 1-7 wherein R_3
5 is COR_7 .

9. A compound according to claim 8 wherein R_7 is C_1-C_4
alkyl, phenyl, furanyl or thienyl optionally substituted
with halogen, $NR_8 R_9$ wherein R_8 and R_9 are each
10 independently hydrogen or C_1-C_4 alkyl, or C_1-C_4 alkoxy.

10. A compound according to claim 8 wherein R and R_4 are
hydrogen, R_1 and R_2 are n-propyl and R_7 is methyl,
ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl,
15 t-butyl, cyclobutyl, thienyl, furanyl, phenyl, amino, N-
methyldamino, methoxy or fluorophenyl.

11. A compound according to any of claims 1-7 wherein R_3
is phenyl, furanyl, thienyl or fluorophenyl.
20

12. A compound according to any of claims 1-7 wherein R_3
is n-propyl, i-propyl, i-propenyl or allyl.

13. A compound according to any of claims 1-9, 11-12
25 wherein R_4 is halogen in 8 position.

14. A compound according to claim 1 which is
3-dipropylamino-5-acetylchroman,
3-dipropylamino-5-carbamoylchroman,
30 3-dipropylamino-5-N-methylcarbamoylchroman and
3-dipropylamino-5-(2-thienylcarbonyl)chroman.


15. A compound according to claim 1 wherein R_3 is CN, COOH,
COCl, COBr, Br, N_3 , NO_2 , SO_3CF_3 or NH_2 , and X, R, R_1 , R_2
35 and R_4 , are as defined in claim 1, an enantiomer or a salt
thereof.

16. A compound according to claim 15 wherein R_1 and R_2 are the same or different and selected from hydrogen, n-propyl, i-propyl and cyclopropyl.

5 17. A compound according to claim 16 wherein R and R_4 are hydrogen, R_1 and R_2 are n-propyl and R_3 is SO_3CF_3 .

18. A pharmaceutical preparation containing as active ingredient a compound according to formula I

10



15

wherein

20

X is O or $\begin{matrix} (O)_p \\ || \end{matrix}$ S;

25

p is an integer 0, 1 or 2;

R is hydrogen, fluoro or C_1 - C_6 alkyl;

30

R_1 is hydrogen, C_1 - C_6 alkyl or C_2 - C_6 alkenyl;

R_2 is hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_1 - C_4 alkylaryl where aryl may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF_3 , C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_1 - C_4 alkoxy; or

35

R_1 and R_2 may together form a 5- or 6- membered

ring which may contain 1 or 2 heteroatoms selected from N, O or S;

5 R_3 is halogen, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl, NR_5 , R_6 , COR_7 , 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and being either (i) optionally substituted by one or more substituents independently selected from
10 halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl or C_1-C_4 alkoxy or either (ii) fused at two adjacent carbon atoms to an aryl ring, said aryl ring being optionally substituted by one or more substituents independently selected from halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl or C_1-C_4 alkoxy;

15

R_4 is hydrogen alkyl or halogen;

R_5 is hydrogen, C_1-C_6 alkyl or C_2-C_6 alkylen;

20

R_6 is C_1-C_6 alkyl or C_2-C_6 alkylen; or

R_5 and R_6 may together form a 5- or 6- membered ring which may contain 1 or 2 heteroatoms selected from N, O or S;

25

R_7 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_4 alkoxy, NR_8 , R_9 or 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by one or more of
30 halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_1-C_4 alkoxy;

35

R_8 and R_9 are each independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, 5- or 6- membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S optionally substituted by halogen, CN, CF_3 , C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_4 alkoxy or may

together form a 5- or 6-membered ring containing 1
or 2 heteroatoms selected from N, O or S;

an enantiomer or a pharmaceutically acceptable salt
5 thereof.

19. A pharmaceutical preparation according to claim 18
wherein R, R₁, R₂, R₃, R₄, R₇, R₈ and R₉ are defined as
in any of claims 7-14.

10

20. A compound according to any of claims 6-14 for use in
the treatment of disorders in the centralnervous system,
especially 5-hydroxy tryptamine medicated disorders.

15 21. A compound according to claim 20 for use in the treat-
ment of depression, anxiety, anorexia, senile dementia,
migraine, Alzheimer's disease, hypertension, termoregulator
and sexual disturbances, pain and disturbances in the
cardiovascular system.

20

22. Use of a compound according to any of claims 6-14 for
the manufacture of a medicament for treatment of disorders
in the central nervous system, especially 5-hydroxy trypt-
amine medicated disorders.

25

23. Use according to claim 22 for the manufacture of a
medicament for treatment of depression, anxiety, anorexia,
senile dementia, migraine, Alzheimer's disease, termo-
regulator and sexual disturbances, pain and disturbances
30 in the cardiovascular system.

24. A method for treatment of disorders in the central
nervous system, especially 5-hydroxytryptamine mediated
disorders by administering to mammals and man a compound
35 defined in any of claims 6-14, an enantiomer or a
physiologically acceptable salt thereof.


25. A method according to claim 24 for treatment of depression, anxiety, anorexia, senile dementia, migraine, Alzheimer's disease, termoregulator and sexual disturbances, pain and disturbances in the cardiovascular system.

5

26. A process for the preparation of a compound of the formula I according to any of claims 1-17, by

a) converting a compound of formula II

10




15

wherein Y is a leaving group and X, R, R₁, R₂ and R₄ are as defined under formula I by a catalytic cycle using a zerovalent transition metal (M), which undergoes an oxidative addition to the aryl-Y-bonds, treatment with carbon monoxide followed by Z-H, where Z is Cl, Br, OH, OR_p, where R_p is C₁-C₆ alkyl, and the initially formed carbonylated σ-aryl-metal-Y complex, to formation of a compound of formula I wherein R₃ is COZ (IA).

25

b) reaction by a catalytic cycle using a zerovalent transition metal (M⁰) which undergoes an oxidative addition to Z-Y, wherein Z is defined Cl, Br, OH, OR_p, where R_p is C₁-C₆ alkyl and Y is a leaving group, treatment with carbon monoxide, followed by addition of the compound of the formula III


30



35

wherein X, R, R₁, R₂ and R₄ are as defined under formula I and M^I is a transition metal to formation of a compound of formula I wherein R₃ is COZ (IA).


5 c) converting a compound of formula II



wherein X, R, R₁, R₂ and R₄ are as defined under formula I
 15 and Y is a leaving group such as SO₃CF₃, halide by treatment with a cyanide reagent, to formation of a compound of formula I wherein R₃ is CN (IB).


d. amination of a compound of formula IA

20



wherein X, R, R₁, R₂, and R₄, are as defined under formula I and Z is Cl, OH or OR_p, where R_p is C₁-C₆ alkyl by reaction with NHR₈R₉ to give the corresponding amide of
 35 formula I, where R₃ is CONR₈R₉ (IC).


- e) Wittig reaction of a 5-carboxy compound of formula I wherein R_3 is COR_7 (ID)



- and X , R , R_1 , R_2 and R_4 are as defined under formula I
 15 and R_7 is alkyl, alkenyl or aryl by using a dipolar reagent to formation of a compound of formula I wherein R_3 is a C_2-C_6 alkenyl group, (IE).

- f) catalytic hydrogenation of a compound of formula I
 20 wherein R_3 is a C_2-C_4 alkenyl group to obtain a compound of the formula I where R_3 is a C_1-C_6 alkyl group (IF).

- g) substitution of a 5-bromochroman/thiochroman deriva-
 tive
 25




35

- wherein X , R , R_1 , R_2 and R_4 are as defined under formula I by treatment with a stannictrialkyl reagent in presence of

a zerovalent metal e.g. Pd⁰ to obtain a compound of formula I wherein R₃ is C₁-C₆ alkyl, C₂-C₆ alkylen or aryl or in presence of carbonmonoxide formed a compound where R₃ is COR₇, where R₇ is C₁-C₆ alkyl, C₂-C₆ alkylen or aryl.


h) converting the 5-carboxychroman/thiochroman derivative of formula IA

10



15

IA



ID


20

wherein X, R, R₁, R₂ and R₄ are defined as in formula I and Z is Cl, Br by using R₇Li to obtain corresponding compound of formula I when R₃ is COR₇ (ID) where R₇ is defined as C₁-C₆ alkyl, C₂-C₆ alkenyl or aryl;

25

i) hydrolysis of a compound of formula I wherein R₃ is CN (IB)

30



35


IB

wherein X, R, R₁, R₂ and R₄ are as defined under formula I optionally followed by treatment with thionylhalide to obtain a compound of formula I wherein R₃ is COZ, where Z is OH, Cl or Br (IA)

5

j) substitution of a compound of formula I wherein R₃ is CN

10



IB


wherein X, R, R₁, R₂ and R₄ are as defined under formula I by treatment with an organometallic reagent followed by hydrolysis to obtain a compound of formula I wherein R₃ is COR₇, where R₇ is C₁-C₆ alkyl, C₂-C₆ alkenyl or aryl (ID);

k) Hydrogenation of a 5-alkene thiochroman/chroman derivative of formula I wherein R₃ is a C₂-C₆ alkenyl group by using H₂/Pd, H₂/Pt or H₂/Raney Ni or potassium azodicarboxylate to formation of corresponding thio-chroman/chroman derivative of formula I wherein R₃ is C₁-C₆ alkyl;

25

l) converting a compound of formula II

30



II


wherein Y is a leaving group and X, R, R₁, R₂ and R₄ are as defined under formula I by reaction with a transition metal, to form a ligand complex which undergoes an oxidative addition by treatment with a trialkylalkenyl-

35

stannane, to formation of a compound of formula I wherein R_3 is a C_2-C_6 alkenyl group.

m) converting a compound of formula II

5



II


10

wherein Y is a leaving group and X, R, R₁, R₂ and R₄ are
 15 as defined under formula I by a reaction with a transition
 metal to form a ligand complex, which undergoes an oxida-
 tive addition by treatment with a trialkylaryl stannane or
 aryl-boric acid reagents, to formation of a compound of
 formula I wherein R₃ is a 5-6-membered aryl which may
 20 contain 1 or 2 heteroatoms selected from N, O or S being
 either substituted or fused at two adjacent carbon atoms;
 whereupon optionally a base obtained is converted to a
 acid addition salt or a salt obtained is converted to the
 base or to a different, acid addition salt, or optionally
 25 an isomeric mixture obtained is separated to a pure
 enantiomer.

27. Compounds, processes, pharmaceutical preparations, use
 of and method of treatment as claimed in any of claims 1-
 30 26 and substantially described.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 90/00863

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶				
According to International Patent Classification (IPC) or to both National Classification and IPC				
IPC5: C 07 D 311/58, 335/06, A 61 K 31/35, 31/38				
II. FIELDS SEARCHED				
Minimum Documentation Searched ⁷				
Classification System	Classification Symbols			
IPC5	C 07 D			
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸				
SE,DK,FI,NO classes as above				
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹				
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³		
X	Chemical Abstracts, vol. 107, 1987, "Preparation of 3-aminodihydro[1]benzopyran and benzothiopyran derivatives as serotonergic agonists", abstract 39617j, & JP 62 59273 (CIBA-GEIGY A.G.) see especially reg.no. 109140-40-1 --	1-23,26-27		
X	J. Med. Chem., vol. 15, 1972, I.M. Lockhart et al: "3-Chromanamine Hydrochlorides with Central Stimulant Activity", pages 863-865 see the whole article --	1-2,6-23,26-27		
X	EP, A2, 0222996 (CIBA-GEIGY AG) 27 May 1987, see especially pages 1-9 --	1-23,26-27		
X	EP, A1, 0280269 (CIBA-GEIGY AG) 31 August 1988, see especially pages 1-5 --	1-23,26-27		
<p>* Special categories of cited documents:¹⁰</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 50%; border: none;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </td> </tr> </table>			<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>			
IV. CERTIFICATION				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report			
18th March 1991	1991 -03- 27			
International Searching Authority	Signature of Authorized Officer			
SWEDISH PATENT OFFICE	 Göran Karlsson			

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	WO, A1, 8804654 (ASTRA LÄKEMEDEL AKTIEBOLAG) 30 June 1988, see especially pages 1-2 and 27-29 -- -----	1-2,6- 23,26- 27

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers 24, 25 because they relate to subject matter not required to be searched by this Authority, namely:

A method for treatment of the human or animal body, see rule 39.

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 90/00863**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on **91-02-28**
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0222996	87-05-27	AU-B- 596113	90-04-26
		AU-D- 6231786	87-03-05
		JP-A- 62059273	87-03-14
EP-A1- 0280269	88-08-31	AU-D- 1234788	88-09-01
		JP-A- 63277671	88-11-15
		US-A- 4801605	89-01-31
		ZA-A- 8801375	88-08-29
WO-A1- 8804654	88-06-30	AU-D- 1082988	88-07-15
		EP-A- 0279150	88-08-24